| Identification | Back Directory | [Name]
1H-Benzimidazole-6-carboximidamide, 2,2'-[1,4-butanediylbis(oxy-4,1-phenylene)]bis-, hydrochloride (1:4) | [CAS]
1366126-19-3 | [Synonyms]
DB2115 tertahydrochloride
1H-Benzimidazole-6-carboximidamide, 2,2'-[1,4-butanediylbis(oxy-4,1-phenylene)]bis-, hydrochloride (1:4) | [Molecular Formula]
C32H31ClN8O2 | [MOL File]
1366126-19-3.mol | [Molecular Weight]
595.1 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture | [solubility ]
DMSO : 10 mg/mL (14.19 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 80°C) | [form ]
Solid | [color ]
Blue to purple |
| Hazard Information | Back Directory | [Uses]
DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) [1]. | [Biological Activity]
DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for the treatment of cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) [1]. | [storage]
4°C, away from moisture | [References]
[1]. W. David Wilson, et al. Pu.1 inhibitors. Patent WO2017223260A1. |
|
|